Illumina launched a semiconductor-based sequencing system—iSeq 100t for single cell genome sequencing market

 

Single cell genome sequencing is one of the promising areas of research for finding a cure for chronic diseases such as cancer. This technology can help in identifying the tumor microenvironment. Thus, the growing prevalence of cancer is driving the growth of the single cell genome sequencing market. Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The most common in 2020 (in terms of new cases of cancer) were: breast (2.26 million cases), colon and rectum (1.93 million cases), skin (non-melanoma) (1.20 million cases); and stomach (1.09 million cases). Therefore, the continous launch of new therapies for the treatment of cancer such as personalized medicine is projected to augment the growth of the single cell genome sequencing market. For instance, Oxford Nanopore, in 2017, launched two sequencing kits— for direct or PCR cDNA analysis that facilitate easy use and provide results in reduced time and cost.

In January 2018, Illumina launched a semiconductor-based sequencing system—iSeq 100t that uses sequencing-by-synthesis chemistry coupled with CMOS detection technology

In June 2018, QIAGEN launched QIAseq 16S/ITS Panels and UCP Multiplex PCR Kit with a new generation of reagents that enables the most accurate microbial community profiling from complex microbiome samples and is used for single cell sequencing

In January 2018, Thermo Fisher Scientific and Illumina Inc. entered a commercial agreement, under which Illumina could sell Ion AmpliSeq technology to researchers who conduct scientific studies on Illumina’s next-generation sequencing (NGS) platforms

North America is projected to hold a dominant position in the market over the forecast period owing to the high prevalence of various types of cancer is in the U.S. According to a report by the American Cancer Society, 2018, cancer is the second leading cause of death after cardiovascular disease. The report further projected around 1.7 million new cases of cancer with around half a million deaths, worldwide.

Single cell genome sequencing has become an integral part of the field of genetic engineering and research. Single cell nuclear genome (SCN) is the sequencing of an individual cell for the purpose of genome sequencing. Single cell nuclear genome (SCN) sequencing is a specialized form of whole-genome sequencing, where instead of sequencing the entire genome, single cells are sequenced. The main advantage of Single cell nuclear genome sequencing over traditional whole-genome sequencing is that it provides higher quality data for personalized applications.

One of the main uses of Single cell genome sequencing is in the field of personalized medicine. The applications of Single cell genome sequencing range from studying the effects of small mutations of DNA on disease traits to designing and personalizing medicines.